President Trump on Thursday claimed his recent “most favored nation” executive order could cause U.S. drug prices to “drop like a rock” in just a matter of weeks, saying ...

BMO Capital Markets reaffirmed its “Outperform” rating on Tourmaline Bio, Inc. (NASDAQ:TRML) with a price target of $35. The ...

Eikon Therapeutics, a Bay Area biotech startup with $1.1 billion in funding, is laying off dozens of employees and pointing ...

Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total ...

Rapper Kid Cudi told a jury Sean "Diddy" Combs broke into his Los Angeles home after the hip-hop mogul found out he was ...

STAT reporters chat about the mood in the gene editing field, M&A deals in biotech, and leadership changes at Novo Nordisk.

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing a total deal value of $470 million.

The Trump administration has revoked a $44 million dollar grant intended for the Birmingham area to bolster Biotechnology ...

Nine states in the Southeast showed growth in bioscience employment and establishments from 2019 to 2023, according to 2024 ...

Congress has not been able to reauthorize environmental statutes for years, with some (most) needing significant attention. EPA relies on 1990 Clean Air Act amendments to sort out air pollution issues ...

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...

Vigil Neuroscience shares more than tripled in premarket trading a day after Sanofi agreed to acquire Vigil for about $470 million. Vigil shares were trading around $8. The stock was up 36% on the ...